Login
$ONCO
$2.95 +$0.04 (1.37%) After hours

$ONCO 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Submission of Matters to a Vote of Security Holders

On November 10, 2026, Onconetix, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were:

09 Nov 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Onconetix, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows:

06 Nov 2026 8-K: Entry into a Material Definitive Agreement

This First Amendment to the Share Exchange Agreement (this “Amendment”) is made as of November 4, 2026, by and among (i) Onconetix, Inc., a Delaware corporation (“Buyer”), (ii) Realbotix Corp., a company existing under the laws of the Pr...

26 Oct 2026 8-K: Other Events

CINCINNATI, Ohio, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”), today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of the Company’s outstanding common...

23 Oct 2026 8-K: Other Events

On October 22, 2026, Onconetix, Inc. (the “Company”) made an additional advance of $500,000 to Realbotix, LLC (“Realbotix”) pursuant to that certain Grid Promissory Note, dated September 11, 2026 (the “Note”), previously disclosed in the...

14 Sep 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR ANY U.S. STATE. SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECT...

29 Jul 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of July 28, 2026 (this “Agreement”), by and among [_______________], a [______________] (the “Investor”), and Onconetix, Inc., a Delaware corporation (the “Company”).

19 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

CINCINNATI, Ohio, May 19, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions...

14 May 2026 8-K: Other Events

Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study

04 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On April 30, 2026, Onconetix, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). The matters voted on at the Special Meeting were:

24 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Resignation of Andrew Oakley and Thomas Meier as Directors; Elections of Sammy Dorf as Chairman of the Board

27 Mar 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative soluti...

24 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

On March 18, 2026, the Board of Directors (the “Board”) of Onconetix, Inc, a Delaware corporation (the “Company”) appointed David White as Chief Executive Officer of the Company effective as of that date. Karina Fedasz, the immediate pas...

12 Feb 2026 8-K: Entry into a Material Definitive Agreement; Other Events

THIS SHARE EXCHANGE AGREEMENT (this “Agreement”) is made and entered into as of February 11, 2026, by and among (i) Onconetix, Inc., a Delaware corporation (“Buyer”), (ii) Realbotix Corp., a company existing under the laws of the Provinc...

09 Feb 2026 8-K: Submission of Matters to a Vote of Security Holders

On February 3, 2026, Onconetic, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). The matters voted on at the Special Meeting were:

10 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

10 Dec 2025 8-K: Entry into a Material Definitive Agreement

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

29 Oct 2025 8-K: Shareholder Director Nominations

As disclosed in the Preliminary Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by Onconetix, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on October 29, 2025, the Company’s Board of Director...

03 Oct 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

OF RIGHTS AND PREFERENCES OF SERIES E CONVERTIBLE PREFERRED STOCK OF ONCONETIX, INC.

26 Sep 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

OF RIGHTS AND PREFERENCES OF SERIES D CONVERTIBLE PREFERRED STOCK OF ONCONETIX, INC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support